ValiStera ACADEMY

← GMP Foundations course overview

GMP Quality Control, Laboratory Testing and OOS

Lesson 1.7 · Narrated learning · Optional captions and key explanations

Video and companion reading: The supplementary written sections below expand on the recorded lesson and may include later technical or regulatory clarifications. They are not necessarily narrated in the video. For the most complete learning experience, study both the video and the companion reading. Regulatory references are provided for educational use and should be checked against the current official text.

KEY EXPLANATION

Turn captions and key explanations on or off using the controls above.

OOS investigation — supplementary reading

An out-of-specification (OOS) result is not erased or replaced by a passing retest. Preserve the original data, promptly notify the appropriate quality function and follow the approved laboratory OOS procedure. A timely initial laboratory assessment examines possible analytical errors and available evidence. If no scientifically supported laboratory cause explains the result, a full-scale investigation should follow, including manufacturing review as appropriate to the scope of the FDA guidance (chemistry-based laboratory testing).

Invalidating an initial result requires a documented, scientifically justified assignable cause established through investigation. Retesting and resampling must be controlled and scientifically justified; repeating a test until a passing result appears is not acceptable. Out-of-trend (OOT) results may also warrant investigation under the site's trending and quality procedures even when within specification.

Reference for further reading: FDA Guidance for Industry, Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production (May 2022), and applicable GMP requirements. This summary is educational and does not prescribe a universal investigation sequence for every product and market.

Regulatory references for further reading

21 CFR 211.192 · FDA OOS guidance (May 2022; nonbinding recommendations)

Reference links are starting points for the applicable legal or guidance text. Check current versions and jurisdiction-specific applicability; this training is not a regulatory determination.

Readable guide to the video diagrams

Text descriptions of the main slide relationships, in presentation order. Use these with the narration transcript and companion reading. Arrows summarize relationships; they do not replace site procedures or prescribe a universal workflow. The repeated right-hand panels are reminders, not additional mandatory steps.

  1. Quality control: sample, analyze and review. Testing supports GMP controls.
  2. Specification control links method, test and approved criteria.
  3. Sampling chain of custody: identify the sample, control handling and trace analysis.
  4. Instrument readiness covers calibration, suitability and records.
  5. OOS response: preserve the original result, investigate and assess impact. Retesting requires justification and approval.
  6. Laboratory integrity includes raw data, metadata and audit trails.
  7. Batch disposition integrates records, testing and deviations before an authorized release decision.
  8. Failed-assay example: preserve, report, investigate and decide. Do not replace a failing result without justification.
Read the recorded narration transcript

This transcript follows the existing recording. Read the technical clarifications and companion material as well.

00:00:00 Quality control helps determine whether materials and products meet approved quality

00:00:04 requirements. It includes appropriate sampling,

00:00:07 specifications, testing, documentation and review. Quality

00:00:12 cannot be assured by final testing alone, so laboratory controls work

00:00:17 alongside manufacturing controls. Quality control

00:00:20 activities should be independent where required

00:00:23 by the applicable quality system and regulations.

00:00:26 A specification describes tests, analytical procedures and acceptance criteria for a

00:00:32 material or product. Approved methods should be suitable for their intended

00:00:36 use, with validation or verification as appropriate. Analysts must use current

00:00:42 controlled procedures and suitable reference standards. Results should be compared against

00:00:47 the actual approved specification, not an assumed industry-wide number.

00:00:53 Sampling plans should consider the material, process, risk and intended test.

00:00:58 Samples must be appropriately identified, collected, handled and stored to preserve

00:01:03 integrity. A result from a poorly selected or compromised sample may

00:01:08 not represent the batch. Sampling procedures and any required environmental controls

00:01:13 should be defined and followed. Traceability links each sample to its

00:01:18 source and analysis.

00:01:20 Laboratory instruments must be suitable for their intended measurements. Qualification, calibration,

00:01:26 maintenance and system suitability checks may be needed depending on the

00:01:30 equipment and method. Analysts should verify instrument status before use and

00:01:35 preserve relevant records. A successful system

00:01:38 suitability check does not automatically

00:01:41 excuse overdue calibration or missing qualification evidence.

00:01:46 An out-of-specification result, often called OOS, occurs when a

00:01:51 result falls outside an established acceptance

00:01:53 criterion. Such results require timely,

00:01:57 documented evaluation under applicable procedures.

00:02:01 A laboratory investigation may examine potential

00:02:04 analytical errors, while the wider assessment

00:02:06 considers manufacturing and product impact

00:02:09 where appropriate. Retesting must follow justified approved procedures and must not

00:02:16 be used simply to obtain a passing result.

00:02:19 Laboratory data must be attributable, legible,

00:02:22 contemporaneous, original and accurate, with

00:02:25 additional expectations for completeness, consistency,

00:02:29 endurance and availability. Electronic raw data,

00:02:32 audit trails, calculations and relevant metadata should be controlled according to

00:02:36 risk and applicable requirements. Transcribing

00:02:39 a final number without retaining required

00:02:42 underlying data may undermine traceability and review.

00:02:46 Batch disposition decisions rely on more than a passing laboratory result.

00:02:51 Authorized personnel should evaluate relevant manufacturing records, deviations, testing results, specifications

00:02:58 and other required evidence. Responsibilities and legal release requirements vary by

00:03:04 jurisdiction and product. A laboratory analyst should not independently declare a

00:03:10 batch releasable merely because a single test passed.

00:03:13 Imagine a finished-product assay result outside

00:03:17 its approved specification. The analyst

00:03:19 should preserve the original data and promptly report the result according

00:03:23 to the laboratory procedure. Authorized personnel should conduct an appropriate investigation

00:03:28 and assess possible batch impact. The result must not be deleted,

00:03:33 averaged away or replaced by an unjustified repeat test. The documented

00:03:38 outcome informs the final quality decision.

Check your understanding

What should happen when a finished-product assay result is outside its approved specification?

Choose one answer

Continue to Lesson 1.8 →

Return to course overview →